Advanced Container Technologies Inc (ACOL) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
52 |
Employees |
22 |
Revenues (TTM) (Millions $) |
5 |
Net Income (TTM) (Millions $) |
-1 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Advanced Container Technologies Inc
Through D&C Distributors LLC, we are in the business of selling proprietary
plastic medical grade containers under the registered trademark “Medtainer®"
that can store pharmaceuticals, herbs, teas and other solids or liquids, some
of which can grind solids and shred herbs. We have received child safety certification
for our 20-dram container and we are focusing our marketing efforts on drug
stores and drug store chains, veterinarians and veterinary distributors and
other distributors and end users. Through D&C Printing LLC, we are in the
business of private labeling and branding for purchasers of containers and other
products.
Through D&C Distributors LLC and and D&C Printing LLC, we are in the
business of selling and distributing patented containers that can store, grind
and shred pharmaceuticals, herbs, teas and other solids or liquids that are
described under the caption “Description of Business – Products
– The Medtainer®.” We provide custom printing of labeling for
our products and products manufactured by others, as described under the caption,
“Description of Business – Printing.”
We market directly to businesses through our phone room to the retail public
through internet sales and, and to wholesalers and other businesses who resell
our products to other businesses and end users.
Some of our products can be utilized for marijuana-related purposes. In light
of the facts that the possession and use of marijuana have been legalized, subject
to varying restrictions, in many states and that several other states are considering
such legalization, we believe that our products may be of interest to a large
number of users of marijuana in and we advertise our products on our website
and elsewhere as suitable for that purpose. However, since we do not seek information
from our customers who are end users as to how they intend to utilize our products
and have no similar knowledge respecting end users of products sold through
our distributor, we are unable to determine the extent of its use in connection
with the storage and grinding of marijuana or any other purpose. We believe
that marketing these products subjects us to the following risks.
The use of marijuana for medical and recreational use is lawful in many states,
but under United States federal law and the laws of the other states, the possession,
use, cultivation, storage, processing and/or transfer of marijuana is illegal.
Federal and state law enforcement authorities have prosecuted persons engaged
in these activities. While we do not believe that we engage in any of these
activities, any of these law enforcement authorities might bring an action against
us in connection with the engagement of others in them, including, but not limited,
to a claim of aiding and abetting their criminal activities. Such an action
would have a material and adverse effect on our business and operations.
· Under United States federal law, it is unlawful to sell or offer for
sale, to use the mails or any other facility of interstate commerce to transport
or to import or export drug paraphernalia. The term “drug paraphernalia”
includes any equipment, product or material of any kind which is primarily intended
or designed for use in manufacturing, compounding, converting, concealing, producing,
processing, preparing, injecting, ingesting, inhaling, or otherwise introducing
into the human body a controlled substance. One of the factors that these authorities
may consider in determining whether our products are drug paraphernalia are
our national and local advertising concerning its use and we have advertised
our products as usable for marijuana-related purposes. However, we do not believe
that our products were designed or are intended for any of these purposes or
that our products are drug paraphernalia, as defined in federal law, and we
are promoting our products primarily to be used for other purposes. If federal
authorities were to take a different view, they might bring a criminal action
against us. Such an action would have a material and adverse effect on our business
and operations. During the administration of President Barack H. Obama, enforcement
of such federal law was relaxed, but there have been indications that the administration
of President Donald J. Trump may enforce it differently. We are presently unable
to predict what effect, if any, this change, if it occurs, would have on us
or our business.
Company Address: 1620 Commerce St. Corona 92878 CA
Company Phone Number: 381-2555 Stock Exchange / Ticker: ACOL
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Exagen Inc
Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior. Although there was a 7.229% increase in revenue to $13.77 million from $12.84 million in the corresponding reporting season, this is a relatively small growth rate and not enough to inspire confidence in the company's prospects. The sequential revenue growth of 2.601% from $13.42 million is also modest at best.
|
Enzo Biochem Inc
Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low. For the financial second quarter of 2024, Enzo Biochem Inc reported a significant improvement in its earnings per share (EPS) compared to the previous year. The loss per share decreased from $-0.23 to $-0.06. Furthermore, the EPS also improved from the preceding quarter, going from $-0.13 to $-0.06.
|
Ispecimen Inc
iSpecimen Inc. (Nasdaq: ISPC) is a pioneering online marketplace that connects scientists with healthcare specimen providers for research purposes. The company, headquartered in Lexington, Massachusetts, has recently announced that it will unveil its full-year financial results for the period ending December 31, 2023, on March 13, 2024. Stakeholders are eagerly awaiting the release of these results, as iSpecimen is globally recognized for its innovative platform that facilitates breakthrough discoveries and accelerates scientific advancements. The previous fiscal span, from October to December 31, 2023, saw iSpecimen Inc. experience a deficit per share of $-0.33, compared to $-0.20 the previous year. This represents a growth in deficit per share from $-0.23 from the prior reporting season. Additionally, the company's revenue declined by -13.049% to $2.58 million from $2.96 million in the comparable reporting season a year before. Sequentially, revenue deteriorated by -7.296% from $2.78 million.
|
Maxcyte Inc
Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share. Despite the positive revenue growth, Maxcyte Inc's shares have gone down by -15.63% in the past 5 trading days and -14.35% from a year ago. Currently, the company's shares are trading on the NASDAQ by -8.4% below its 52 week average.
|
Butterfly Network Inc
Butterfly Network Inc Reports Decreased Loss Per Share, Declining Revenue for Q4 2023 BURLINGTON, Mass. and NEW YORK - Butterfly Network, Inc. (NYSE: BFLY), a digital health company focused on portable, semiconductor-based ultrasound technology, announced its financial results for the quarter and year ended December 31, 2023. The company also provided an update on its business activities. Butterfly Network aims to make medical imaging more accessible through its innovative product offerings, software solutions, and educational programs. For the financial period closing December 31, 2023, Butterfly Network reported a loss of $-0.21 per share, showing an improvement from the loss of $-0.31 per share in the previous year. However, there was an increased loss compared to the previous reporting period, from $-0.13 per share. The company's revenue declined by 14.346% to $17.08 million from $19.94 million, in the comparable reporting period a year prior. Nevertheless, sequentially, the revenue advanced by 11.013%, from $15.38 million.
|
Per Share |
Current |
Earnings (TTM) |
-0 $ |
Revenues (TTM) |
0.09 $
|
Cash Flow (TTM) |
- |
Cash |
0.01 $
|
Book Value |
0.02 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0 $
|
Revenues (TTM) |
0.09 $ |
Cash Flow (TTM) |
- |
Cash |
0.01 $
|
Book Value |
0.02 $ |
Dividend (TTM) |
0 $ |
|
|
|
|